[1] |
WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying .
Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration
[J]. China Oncology, 2021, 31(9): 775-782.
|
[2] |
LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin.
The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer
[J]. China Oncology, 2021, 31(9): 838-844.
|
[3] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
[4] |
LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun .
miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene
[J]. China Oncology, 2021, 31(7): 581-588.
|
[5] |
YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang .
The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province
[J]. China Oncology, 2021, 31(7): 616-628.
|
[6] |
XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia.
The advances in immunotherapy biomarkers of small cell lung cancer
[J]. China Oncology, 2021, 31(7): 635-639.
|
[7] |
QIAO Tingting , GE Shujing , LUO Yuan , LU Chengrong , DUAN Lianning .
Mechanism of inhibition of epithelial-to-mesenchymal transition by phosphorylated H2AX in lung cancer cells
[J]. China Oncology, 2021, 31(4): 277-284.
|
[8] |
MU Lina , SU Jia , YU Shunzhang , NIU Rungui , HAN Xiaoyou , LIU Li , SHI Jianping , ZHANG Zuofeng .
The control of lung cancer relating to quitting active smoking and secondary smoking: a case-control study of lung cancer in Taiyuan
[J]. China Oncology, 2021, 31(4): 335-343.
|
[9] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[10] |
ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li .
Advances in the treatment of BRAF V600-mutant non-small cell lung cancer
[J]. China Oncology, 2021, 31(12): 1145-1152.
|
[11] |
WU Ran , WANG Guizhen , CHENG Xin , ZHOU Guangbiao .
The effects of copper ion on cell proliferation and the clinical significance of copper ion in lung cancer
[J]. China Oncology, 2021, 31(11): 1072-1080.
|
[12] |
SHEN Yujia , FU Xiaolong .
Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer
[J]. China Oncology, 2021, 31(11): 1115-1125.
|
[13] |
LIU Qian , QIAO Meng , MAO Shiqi , YANG Shuo , LIU Yiwei , ZHAO Chao , LI Xuefei , REN Shengxiang , ZHOU Caicun .
Impact of metastatic organ on prognosis in extensive-stage small cell lung cancer
[J]. China Oncology, 2021, 31(1): 45-51.
|
[14] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
[15] |
ZHANG Cuicui, QIN Tingting, MENG Zhaoting, LI Kai.
Research advances in abnormal lipid metabolism of lung cancer
[J]. China Oncology, 2021, 31(1): 76-80.
|